BioAtla (NASDAQ:BCAB) PT Lowered to $7.00 at HC Wainwright

BioAtla (NASDAQ:BCAB) had its price objective trimmed by HC Wainwright from $10.00 to $7.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for BioAtla’s FY2028 earnings at ($0.09) EPS.

Separately, JMP Securities reiterated a market outperform rating and set a $12.00 price objective on shares of BioAtla in a research note on Tuesday, December 5th.

BioAtla Trading Down 0.6 %

Shares of NASDAQ BCAB opened at $3.44 on Wednesday. The business has a fifty day simple moving average of $2.53 and a 200 day simple moving average of $2.10. The firm has a market capitalization of $164.91 million, a price-to-earnings ratio of -1.33 and a beta of 1.02. BioAtla has a one year low of $1.24 and a one year high of $4.07.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BCAB. Swiss National Bank raised its stake in BioAtla by 17.8% during the first quarter. Swiss National Bank now owns 50,200 shares of the company’s stock worth $251,000 after acquiring an additional 7,600 shares in the last quarter. BlackRock Inc. raised its stake in BioAtla by 0.5% during the first quarter. BlackRock Inc. now owns 1,594,238 shares of the company’s stock worth $7,970,000 after acquiring an additional 8,344 shares in the last quarter. Ergoteles LLC acquired a new position in BioAtla during the first quarter worth $79,000. Prudential Financial Inc. acquired a new position in BioAtla during the first quarter worth $130,000. Finally, XTX Topco Ltd acquired a new stake in shares of BioAtla in the first quarter valued at $91,000. 77.23% of the stock is currently owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.